$CADL

Candel Therapeutics (CADL) reported phase 2a trial results showing median overall survival of 24.5 months in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors. The trial involved 46 patients treated with aglatimagene besadenovec plus valacyclovir. Results were published in the Journal for ImmunoTherapy of Cancer. The company is advancing a phase 3 trial (AURORA) for this treatment.

Candel Therapeutics (CADL) presented data at ASTRO 2026 showing aglatimagene besadenovec significantly increased immune response in prostate cancer patients over two years. The phase 3 trial showed 80% of aglatimagene patients had negative biopsies vs. 63% of controls. The company plans to submit a BLA based on these results.

Candel Therapeutics (CADL) shares rose 9.3% premarket after BofA Securities upgraded the stock to Buy and raised the price target to $18.00 from $12.00, citing positive outlook for the biotech sector and key catalysts.

U.S. stock futures rose overnight after the Federal Reserve's 25 basis point rate hike, with Dow, S&P 500, and Nasdaq futures up 0.62%, 0.56%, and 0.57% respectively. The Fed's target rate now ranges from 3.75% to 4.00%. SpaceX (SPCX) shares climbed over 5% on Morgan Stanley's positive rating, while Fluence Energy (FLNC) dropped 15% after cutting fiscal 2026 guidance. Snap (SNAP) gained 2% after unveiling new AI products.

Tak Paul Peter (Chief Executive Officer) sold 280,245 shares of Candel Therapeutics, Inc. (CADL) at an average of $11.28 ($10.46–$11.50, $3.16M total) across 2 trades over 2026-09-10 to 2026-09-11 under a Rule 10b5-1 trading plan.

Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors • Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness NEEDHAM, Mass.,

Candel Therapeutics (CADL) stock surged over 190% in six months due to clinical progress. CAN-2409 showed 50% 24-month survival in NSCLC and 39% improvement in prostate cancer survival. CAN-3110 is in Phase 1b for glioblastoma. CADL partnered with EVERSANA and plans a BLA filing for CAN-2409 in Q4 2026.

NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.

Candel Therapeutics (Nasdaq: CADL) reported Q2 2026 results and updates. It plans a BLA for aglatimagene in localized intermediate- to high-risk prostate cancer in Q4 2026. Phase 3 data in The Lancet Oncology showed a 39% improvement in prostate cancer-specific DFS vs placebo after 58 months. Cash was $201.6M as of June 30, 2026.

Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights • Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 202